MDM2–309 T>G 基因多态性与东亚人群胃癌风险关系的Meta分析_《中国循证医学杂志》

作者：

冉恒泉 , 周勇 , 陈博 , 杨平 ,  伍晓汀

四川大学华西医院胃肠外科（成都 610041）;

关键词：

胃癌鼠双微体基因2（MDM2）单核苷酸多态性（SNP） Meta分析病例-对照研究

DOI：

10.7507/1672-2531.20130099

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　探讨东亚人群中MDM2 SNP309与胃癌风险的关系。
方法　计算机检索MEDLINE、EMbase和CBM数据库，检索时限均为1990.1.1至2012.12.23，搜集研究东亚人群中MDM2 SNP309与胃癌风险的病例-对照研究。由两位研究者独立进行文献筛选、资料提取和纳入研究的方法学质量评价后，采用RevMan 5.0软件进行Meta分析。
结果　共纳入5个病例-对照研究，包括1 621例胃癌患者，2 639例对照。Meta分析结果显示：与野生型纯合子（309TT）基因型个体相比，变异纯合子（309GG）基因型个体与胃癌风险增高相关［OR=1.54，95%CI（1.04，2.29），P=0.02］，然而杂合子（309TG）基因型个体与胃癌风险增高相关性无统计学意义［OR=1.03，95%CI（0.75，1.42），P=0.006］。在隐形遗传模式中（GG vs. TG/TT）胃癌风险增高且有统计学意义［OR=1.49，95%CI（1.20，1.84），P=0.07］，但在显性遗传模式中（GG/TG vs. TT）这种风险增高无统计学意义［OR=1.18，95%CI（0.84，1.65），P=0.001］。
结论　在东亚人群中，MDM2 309GG基因型个体可能存在较高的胃癌风险。

引用本文： 冉恒泉,周勇,陈博,杨平,伍晓汀. MDM2–309 T>G 基因多态性与东亚人群胃癌风险关系的Meta分析. 中国循证医学杂志, 2013, 13(5): 560-563. doi: 10.7507/1672-2531.20130099 复制

1.	Ahmedin J, Freddie B, Melissa M, et al. Global cancer statistics. Ca Cancer J Clin, 2011, 61(2): 69-90.
2.	Francesco G, Emma DF, Cornelia MvD, et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Current Genomics, 2008, 9(6): 361-374.
3.	Silva F, Carvalho F, Peixoto A, et al. MUC1 gene polymorphism in the gastric carcinogenesis pathway. Eur J Hum Genet, 2001, 9(7): 548- 552.
4.	Correa P, Schneider BG. Etiology of Gastric Cancer: What Is New? Cancer Epidem Biomar, 2005, 14(8): 1865-1868.
5.	Bose I, Ghosh B. The p53-MDM2 network: from oscillations to apoptosis. J Biosci, 2007, 32(5): 991-997.
6.	Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature, 2008, 451(7174): 76-80.
7.	Daujat S, Neel H, Piette J. MDM2: life without p53. Trends in Genetics, 2001, 17(8): 459-464.
8.	Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
9.	Wan Y, Wu W, Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC cancer, 2011, 11(1): 208.
10.	Blok P, Craanen ME, Dekker W, et al. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Patho, 1998, 186(1): 36-40.
11.	Well GA, Shea B, O’COnnell D, et al. the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Heath Research Institute.www.ohri. ca/ programs/ clinical_ epidemiology/ oxford asp(accessed Oct 20, 2012).
12.	Cao YY, Zhang XF, Guo W, et al. Association of the MDM2 polymorphisms with susceptibility of esophageal squamous cell carcinoma and that of gastric cardiac adenocarcinoma. Tumor, 2007, 27(8): 628-632.
13.	Wang XY, Yang J, Ho B, et al. Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 2009, 14(5): 114-119.
14.	Yang M, Guo YL, Zhang XM, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 2007, 28(9): 1996-2001.
15.	Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 2006, 24(27): 4434-4440.
16.	Cho YG, Cho BJ, Song JH, et al. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 2008, 55(3): 256-260.
17.	Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res, 2007, 13(14): 4123-4129.
18.	Heidl G, Langhans P, Mellin W, et al. Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol, 1993, 120(1-2): 95-99.
19.	Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA, 2003, 100(3): 776-781.
20.	Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: Systematic review and meta-analysis. Eur J Hum Genet, 2009, 17(12): 1658-1667.

1. Ahmedin J, Freddie B, Melissa M, et al. Global cancer statistics. Ca Cancer J Clin, 2011, 61(2): 69-90.
2. Francesco G, Emma DF, Cornelia MvD, et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Current Genomics, 2008, 9(6): 361-374.
3. Silva F, Carvalho F, Peixoto A, et al. MUC1 gene polymorphism in the gastric carcinogenesis pathway. Eur J Hum Genet, 2001, 9(7): 548- 552.
4. Correa P, Schneider BG. Etiology of Gastric Cancer: What Is New? Cancer Epidem Biomar, 2005, 14(8): 1865-1868.
5. Bose I, Ghosh B. The p53-MDM2 network: from oscillations to apoptosis. J Biosci, 2007, 32(5): 991-997.
6. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature, 2008, 451(7174): 76-80.
7. Daujat S, Neel H, Piette J. MDM2: life without p53. Trends in Genetics, 2001, 17(8): 459-464.
8. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
9. Wan Y, Wu W, Yin Z, et al. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC cancer, 2011, 11(1): 208.
10. Blok P, Craanen ME, Dekker W, et al. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. J Patho, 1998, 186(1): 36-40.
11. Well GA, Shea B, O’COnnell D, et al. the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Heath Research Institute.www.ohri. ca/ programs/ clinical_ epidemiology/ oxford asp(accessed Oct 20, 2012).
12. Cao YY, Zhang XF, Guo W, et al. Association of the MDM2 polymorphisms with susceptibility of esophageal squamous cell carcinoma and that of gastric cardiac adenocarcinoma. Tumor, 2007, 27(8): 628-632.
13. Wang XY, Yang J, Ho B, et al. Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 2009, 14(5): 114-119.
14. Yang M, Guo YL, Zhang XM, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis, 2007, 28(9): 1996-2001.
15. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 2006, 24(27): 4434-4440.
16. Cho YG, Cho BJ, Song JH, et al. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma, 2008, 55(3): 256-260.
17. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res, 2007, 13(14): 4123-4129.
18. Heidl G, Langhans P, Mellin W, et al. Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol, 1993, 120(1-2): 95-99.
19. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA, 2003, 100(3): 776-781.
20. Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: Systematic review and meta-analysis. Eur J Hum Genet, 2009, 17(12): 1658-1667.

上一篇
血管内皮生长因子与食管癌预后相关性的Meta分析
下一篇
儿童原发性高血压影响因素的Meta分析

《中国循证医学杂志》

MDM2–309 T>G 基因多态性与东亚人群胃癌风险关系的Meta分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国循证医学杂志》

MDM2–309 T>G 基因多态性与东亚人群胃癌风险关系的Meta分析

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料